ADRB2 and gastric neoplasm: Regarding the analysis of the immunoreactivity of beta 2 adrenergic receptors in gastric cancer, we observed an increase in them from well-differentiated tumors (297,704.0 ± 109,812.0) to moderately differentiated gastric tumors (357,031.0 ± 92,350.0) and poorly differentiated gastric tumors (438,204.0 ± 160,859.0).